Login to Your Account



Biosimilars Are at the Top of the FDA’s Shutdown Casualty List

By Mari Serebrov
Washington Editor

Tuesday, October 8, 2013
The first casualties are starting to come in from the partial shutdown at the FDA, with biosimilars at the top of the list. As the shutdown, caused by Congress’ inability to agree on fiscal 2014 funding, stretched into a second week, the FDA clarified what drug review activities would be affected by the lapse in appropriations.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription